Guggenheim Increases Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $43.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price raised by equities research analysts at Guggenheim from $28.00 to $43.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 54.95% from the company’s previous close.

A number of other research firms have also commented on CNTA. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Stephens started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 price objective on the stock. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Finally, Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $34.78.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded up $0.43 during trading hours on Tuesday, reaching $27.75. 96,244 shares of the company traded hands, compared to its average volume of 1,114,206. The stock’s fifty day moving average is $23.36 and its 200 day moving average is $17.65. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $29.29. The stock has a market cap of $3.73 billion, a P/E ratio of -15.12 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Mario Alberto Accardi sold 8,172 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $21.40, for a total transaction of $174,880.80. Following the completion of the transaction, the insider directly owned 197,394 shares of the company’s stock, valued at approximately $4,224,231.60. This represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total transaction of $400,200.00. Following the transaction, the general counsel directly owned 105,386 shares in the company, valued at approximately $2,108,773.86. The trade was a 15.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 179,964 shares of company stock worth $4,106,481. Company insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CNTA. Caitong International Asset Management Co. Ltd increased its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Centessa Pharmaceuticals in the first quarter valued at $47,000. Bank of New York Mellon Corp bought a new stake in Centessa Pharmaceuticals in the first quarter worth $147,000. Fox Run Management L.L.C. bought a new position in Centessa Pharmaceuticals during the first quarter valued at $160,000. Finally, Vestal Point Capital LP bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth about $214,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.